Synthon Seeks To Shift Lilly Adcirca Battle To NC

Law360, New York (April 20, 2010, 2:32 PM EDT) -- Synthon Pharmaceuticals Inc. is seeking to transfer to its home state of North Carolina a patent battle with Eli Lilly & Co. over the generic-drug maker's attempts to introduce its own version of hypertension drug Adcirca.

Synthon filed a motion Monday to dismiss Lilly's complaint in the U.S. District Court for the Southern District of Indiana for lack of personal jurisdiction and lack of proper venue, or in the alternative to transfer it to North Carolina.

The generics maker, which is based in Research Triangle Park,...
To view the full article, register now.